CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 200 enrolled
Drug / intervention
Oxytocin +1 moredrug
Likely dose
Oxytocin 40 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03046836
NCT03046836Phase 2Completed
CompareCT.gov

Effects of Oxytocin on Alcohol Craving and Intimate Partner Aggression

Medical University of South Carolina·interventional·Posted Feb 8, 2017·Updated May 9, 2022

In Brief

A Phase 2 clinical trial evaluating Oxytocin and Placebo for Alcohol Use. Completed, enrolled 200 participants across 1 site.

Detailed Summary

Alcohol use disorders (AUD) and intimate partner aggression (IPA) frequently co-occur. There are significant health and economic burdens associated with AUD and co-occurring IPA, and little empirical data to guide treatment efforts. The neuropeptide oxytocin may help mitigate both AUD and IPA. However, clinical data examining oxytocin's effects on human aggression is scant. The proposed study is designed to address these gaps in the literature by utilizing a human laboratory paradigm to test the effects of oxytocin on craving and aggression among couples with AUD and co-occurring IPA.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcohol Use
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 8, 2017
Enrollment StartJul 1, 2017
Primary CompletionApr 11, 2021
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 9.4 years ago

Interventions

Oxytocindrug

40 IU oxytocin nasal spray

Placebodrug

Saline